Antioncogene PTEN-a new target for myeloma therapy.
- Author:
Su-Yun WANG
1
;
Zhi-Yong CHENG
;
Kai DENG
;
Hao CHEN
;
Lin PAN
Author Information
1. Laboratory of Hematology, Department of Hematology, The Second Hospital Affliated to Hebei Medical University, Shijiazhuang 050000, Hebei Province, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Multiple Myeloma;
metabolism;
therapy;
PTEN Phosphohydrolase;
genetics;
metabolism;
Signal Transduction
- From:
Journal of Experimental Hematology
2010;18(3):816-820
- CountryChina
- Language:Chinese
-
Abstract:
Pten gene is the first antioncogene with dual phosphatase activity discovered so far, pten gene regulates the cell cycle progress, apoptosis, metastasis and invasion of the tumor cells through negatively regulating the multiple signaling transduction pathways. Multiple myeloma (MM) is a malignant tumor occurring in terminal stage of B cell differentiation. The genetic changes are considered as the important factors in MM pathogenesis, among which the deletion of antioncogene is a critical genetic change. However, little is known about the genetic change of pten in MM. This review summarizes the research advance on pten in MM including structure of pten, mechanism of pten effect and correlation of pten with MM in order to provide some references for the investigating new gene target to treat the MM.
